Isomorphic Labs is reported to be in talks to raise about $5bn at a valuation near $50bn
Bloomberg, citing people familiar, says the round is not final and terms could change; the Alphabet drug-discovery unit raised $2.1bn in May.
Why it matters
Isomorphic Labs was spun out of Google DeepMind in 2021 to turn AlphaFold-style protein structure prediction into drug discovery. A round of about $5bn would be more than double the $2.1bn it raised in May in a round led by Thrive Capital with Alphabet taking part. In October, Bloomberg had reported early talks at a valuation of at least $40bn. Watch for a signed term sheet, the lead investors and any first clinical trial of a drug it designed.
Key facts
- Reported round: about $5 billion
- Reported valuation: around $50 billion
- Talks not final; terms could change (Bloomberg sources)
- Raised $2.1 billion in May, led by Thrive Capital
- Spun out of Google DeepMind in 2021